Answers are grounded in this paper and cite their sources.
Small cell lung cancer (SCLC) comprises neuroendocrine (NE) and non-neuroendocrine (non-NE) subtypes with distinct immune landscapes and responses to therapy. Here, we established murine experimental metastases models to investigate RNA vaccination across SCLC subtypes. These exhibited distinct organotrophic properties and differ in both the magnitude and kinetics of interferon-induced MHC-I upregulation. Vaccination controlled non-NE tumors but provided limited survival benefit against NE tumors established in the lung or liver. Single-nucleus RNA sequencing and chromatin accessibility profiling revealed inflammation-associated programs following vaccination shared between organs. To overcome the limited survival benefit of vaccination in NE SCLC, we combined RNA vaccination with liver-targeted RNA-encoded cytokines. This combination markedly prolonged survival of NE tumor-bearing mice and enhanced inflammatory immune activity within the tumor microenvironment. Together, these findings identify vaccination-associated inflammatory programs of potential clinical relevance and warrant further investigation of cytokine combination therapy as strategy to improve immunotherapy in NE SCLC.
No takes yet. Share an insight, caveat, or question.
Schork et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: